ledipasvir/sofosbuvir / Generic mfg. |
NCT02120300: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders |
|
|
| Completed | 2b | 122 | US | LDV/SOF, Harvoni®, GS-5885/GS-7977, SOF, Sovaldi®, GS-7977, PSI-7977, RBV | Gilead Sciences | Chronic HCV Infection | 08/15 | 08/15 | | |
NCT01726517: Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects |
|
|
| Completed | 2 | 100 | US | LDV/SOF, Harvoni®, RBV | Gilead Sciences | Chronic Hepatitis C Virus | 07/13 | 01/14 | | |
|
|
|
|
NCT01260350: Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3 |
|
|
| Completed | 2 | 292 | RoW | SOF, Sovaldi®, GS-7977, PSI-7977, RBV, Copegus®, PEG, Pegasys®, LDV, GS-5885, GS-9669, LDV/SOF, Harvoni® | Gilead Sciences | Chronic Hepatitis C Infection | 10/13 | 12/13 | | |
|
|
|
|
|
|
|
|
NCT01938430: Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant |
|
|
| Completed | 2 | 339 | US | LDV/SOF, Harvoni®, GS-5885/GS-7977, RBV | Gilead Sciences | Chronic HCV Infection | 01/15 | 03/15 | | |
|
|
|
NCT01826981: Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection |
|
|
| Completed | 2 | 359 | RoW | LDV/SOF, Harvoni®, GS-5885/GS-7977, SOF, GS-7977, Sovaldi®, RBV, Peg-IFN, Pegasys®, GS-9669, VEL, GS-5816 | Gilead Sciences | Chronic Hepatitis C | 03/15 | 05/15 | | |
NCT02010255 / 2013-002802-30: Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant |
|
|
| Completed | 2 | 334 | Canada, Europe, RoW | LDV/SOF, Harvoni®, GS-5885/GS-7977, RBV | Gilead Sciences | Chronic HCV Infection | 05/15 | 08/15 | | |
|
|
|
NCT02219685: Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection |
|
|
| Completed | 2 | 40 | US | LDV/SOF, Harvoni®, GS-5885/GS-7977, Placebo | Gilead Sciences | Hepatitis C Virus Infection | 08/15 | 04/16 | | |
LEPTON, NCT02202980: Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection |
|
|
| Completed | 2 | 273 | RoW | LDV/SOF, Harvoni®, GS-5885/GS-7977, RBV, SOF/VEL, Epclusa®, GS-7977/GS-5816, VOX, GS-9857 | Gilead Sciences | Chronic Hepatitis C | 03/16 | 05/16 | | |
NCT02251717 / 2014-002121-35: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection |
|
|
| Completed | 2 | 114 | Europe | LDV/SOF, Harvoni®, GS-5885/GS-7977 | Gilead Sciences | Hepatitis C Virus Infection | 03/16 | 06/16 | | |
NCT02350569: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting |
|
|
| Completed | 2 | 17 | US | LDV/SOF, Harvoni®, GS-5885/GS-7977 | Gilead Sciences | Hepatitis C Virus Infection | 03/16 | 04/16 | | |
NCT02301936: Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease |
|
|
| Completed | 2 | 10 | US | LDV/SOF, Harvoni®, GS-5885/GS-7977 | Gilead Sciences | Hepatitis C Virus Infection | 04/16 | 04/16 | | |
|
| Completed | 2 | 20 | Europe | LDV/SOF FDC | HepNet Study House, German Liverfoundation, Hannover Medical School, Gilead Sciences | Acute Hepatitis C | 08/16 | 08/16 | | |